ArticleEuropean journal of heart failure2023

Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Lars H Lund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.